Archives

  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2021-03
  • 2020-08
  • 2020-07
  • 2020-03
  • 2019-11
  • 2019-10
  • 2019-09
  • 2019-08
  • 2019-07
  • br Conclusions br In the present

    2022-05-04


    5. Conclusions
    In the present study, a new type of PAMAM dendrimer deriva-tive was established. HA was used as the targeting group, and PAMAM was coated with Pt and Dox by a covalent reaction, which were found highly stable, biocompatible, and potent against breast cancer. This design enabled the synergistic killing of breast cancer cells. The dual drug-loaded [email protected] was found to be very stable and entered AZD-5991 through the lysosome-mediate path-way. Cytotoxicity studies were employed in MCF-7 and MDA-MB-231 breast cancer cells, which indicated that [email protected] had a higher anticancer effect than that of monomers. In vivo tissue distribution studies of [email protected] demonstrated that [email protected] showed a remarkable increase in drug accumulation in the tumor tissue when compared with free drug solutions. Moreover, drug distribution studies indicated that after 24 h, almost no drugs were observed in the heart and kidneys, thus indicating that [email protected] may decrease side effects and increase antitumor effi-ciency. The in vivo antitumor efficacy data using MDA-MB-231 tumor-bearing BALB/c mice demonstrated that [email protected] had a stronger antitumor effect than other drug formulations. The present study demonstrated the co-delivery of Pt with Dox to achieve highly efficient ‘‘synergism” in breast cancer cells that may be extended to the other anticancer drugs.
    Declaration of interest
    The authors declare that there is no conflict of interest regard-ing the publication of this paper.
    Acknowledgments
    Appendix A. Supplementary data
    References
    [5] F.M. Muggia, P.S. Braly, M.F. Brady, G. Sutton, T.H. Niemann, S.L. Lentz, R.D. Alvarez, P.R. Kucera, J.M. Small, Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study, J. Clin Oncol. 18 (2000) 106–115.
    [13] L. Liao, J. Liu, E.C. Dreaden, S.W. Morton, K.E. Shopsowitz, P.T. Hammond, J.A. Johnson, A convergent synthetic platform for single-nanoparticle combination cancer therapy: ratiometric loading and controlled release of cisplatin, doxorubicin, and camptothecin, J. Am. Chem. Soc. 136 (2014) 5896–5899.
    [14] N.U. Deshpande, M. Jayakannan, Cisplatin-stitched polysaccharide vesicles for synergistic cancer therapy of triple antagonistic drugs, Biomacromolecules 18 (2017) 113–126. [15] X. Zhang, L. Li, C. Li, H. Zheng, H. Song, F. Xiong, T. Qiu, J. Yang, Cisplatin-crosslinked glutathione-sensitive micelles loaded with doxorubicin for combination and targeted therapy of tumors, Carbohydr. Polym. 155 (2017) 407–415.
    [20] Q. Zhong, S.R.P. da Rocha, Poly(amidoamine) dendrimer-doxorubicin conjugates: vitro characteristics and pseudosolution formulation in pressurized metered-dose inhalers, Mol. Pharmaceut. 13 (2016) 1058–1072. 
    [32] S.H. Chiou, W.T. Wu, Immobilization of Candida rugosa lipase on chitosan with activation of the hydroxyl groups, Biomaterials 25 (2004) 197–204. [33] B. Surnar, K. Sharma, M. Jayakannan, Core-shell polymer nanoparticles for prevention of GSH drug detoxification and cisplatin delivery to breast cancer cells, Nanoscale 7 (2015) 17964–17979. [34] T.C. Chou, Drug combination studies and their synergy quantification using the chou-talalay method, Cancer Res. 70 (2010) 440–446. [35] S.P. Singh, M. Sharma, P.K. Gupta, Cytotoxicity AZD-5991 of curcumin silica nanoparticle complexes conjugated with hyaluronic acid on colon cancer cells, Int. J. Biol. Macromol. 74 (2015) 162–170. [36] K.M. Kitchens, R.B. Kolhatkar, P.W. Swaan, H. Ghandehari, Endocytosis inhibitors prevent poly(amidoamine) dendrimer internalization and permeability across Caco-2 cells, Mol. Pharmaceutics 5 (2008) 364–369. [37] http://www.sciencegateway.org/protocols/cellbio/drug/hcic50.htm.
    [42] B. Surnar, M. Jayakannan, Triple block nanocarrier platform for synergistic cancer therapy of antagonistic drugs, Biomacromolecules 17 (2016) 4075– 4085.
    J. Correia, Hyaluronic acid functionalized green reduced graphene oxide for targeted cancer photothermal therapy, Carbohydr. Polym. 200 (2018) 93–99. [46] T.A. Debele, L.Y. Yu, C.S. Yang, Y.A. Shen, C.L. Lo, pH- and GSH-sensitive hyaluronic acid-MP conjugate micelles for intracellular delivery of doxorubicin to colon cancer cells and cancer stem cells, Biomacromolecules 19 (2018) 3725–3737.
    [60] Z. Wang, S. Sau, H.O. Alsaab, A.K. Iyer, CD44 directed nanomicellar payload delivery platform for selective anticancer effect and tumor specific imaging of triple negative breast cancer, Nanomed. Nanotechnol. Biol. Med. 14 (2018) 1441–1454.